As discussed in Section “Targeting with Anti-CD44 Antibodies,” the anti-CD44v6 antibody conjugated with mertansine showed dose limiting skin toxicity due to CD44v6 expression in non-tumor skin tissue. This evidence concerns the gene CD44 and neoplasm.